References
- Nishino HT, Chang CC. Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis. Arch Pathol Lab Med. 2005;129(10):1299–1310. doi:https://doi.org/10.5858/2005-129-1299-MSCFPA.
- Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–1542. doi:https://doi.org/10.1002/cncr.22570.
- Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45–52. doi:https://doi.org/10.1182/blood-2008-01-134858.
- Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272–281. doi:https://doi.org/10.1007/s11899-015-0269-y.
- Hasserjian RP. Myelodysplastic syndrome updated. Pathobiology. 2019;86(1):7–13. doi:https://doi.org/10.1159/000489702.
- Haferlach T. The molecular pathology of myelodysplastic syndrome. Pathobiology. 2019;86(1):24–29. doi:https://doi.org/10.1159/000488712.
- Wang C, Yang Y, Gao S, et al. Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies. Crit Rev Oncol Hematol. 2018;122:123–132. doi:https://doi.org/10.1016/j.critrevonc.2017.12.013.
- Gill H, Leung AY, Kwong YL. Molecular and cellular mechanisms of myelodysplastic syndrome: implications on targeted therapy. Int J Mol Sci. 2016;17(4):440. doi:https://doi.org/10.3390/ijms17040440.
- Xu JQ, Wang JY, Qin TJ, et al. [Relationship between polymorphisms of tumor necrosis factor alpha gene and primary myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi. 2013;34(10):873–876. doi:https://doi.org/10.3760/cma.j.issn.0253-2727.2013.10.010.
- Uversky VN, El-Baky NA, El-Fakharany EM, et al. Functionality of intrinsic disorder in tumor necrosis factor-α and its receptors. FEBS J. 2017;284(21):3589–3618. doi:https://doi.org/10.1111/febs.14182.
- Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103(1):176–188. doi:https://doi.org/10.1046/j.1365-2141.1998.00933.x.
- Selleri C, Sato T, Anderson S, et al. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165(3):538–546. doi:https://doi.org/10.1002/jcp.1041650312.
- El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. Springerplus. 2016;5(1):1508. doi:https://doi.org/10.1186/s40064-016-3197-y.
- Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol. 2017;3(9):968–974. doi:https://doi.org/10.1200/JCO.2016.71.0806.
- Bestach Y, Nagore VP, Flores MG, et al. Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes. Ann Hematol. 2017;96(8):1287–1295. doi:https://doi.org/10.1007/s00277-017-3036-4.
- Belli CB, Bestach Y, Sieza Y, et al. The presence of -308A TNFα is associated with anemia and thrombocytopenia in patients with myelodysplastic syndromes. Blood Cells Mol Dis. 2011;47(4):255–258. doi:https://doi.org/10.1016/j.bcmd.2011.09.003.
- Powers MP, Nishino H, Luo Y, et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 2007;131(12):1789–1793. doi:https://doi.org/10.5858/2007-131-1789-PITATA.
- Balog A, Borbényi Z, Gyulai Z, et al. Clinical importance of transforming growth factor-beta but not of tumor necrosis factor-alpha gene polymorphisms in patients with the myelodysplastic syndrome belonging to the refractory anemia subtype. Pathobiology. 2005;72(3):165–170. doi:https://doi.org/10.1159/000084121.
- Parnes A, Nikiforow S, Berliner N, et al. Single nucleotide polymorphisms in the human TNF gene are associated with anaemia and neutropenia in a cohort of patients with de novo myelodysplastic syndrome. Br J Haematol. 2010;150(6):700–701. doi:https://doi.org/10.1111/j.1365-2141.2010.08254.x.
- Chen W, Zhu H, Yu L, et al. TNF-α -308 G > A polymorphism and risk of bone marrow failure syndrome: A meta-analysis. Gene. 2015;565(1):1–8. doi:https://doi.org/10.1016/j.gene.2015.04.038.
- Gowans D, O'Sullivan A, Rollinson S, et al. Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology. Br J Haematol. 2002;117(3):541–545. doi:https://doi.org/10.1046/j.1365-2141.2002.03452.x.
- Gyulai Z, Balog A, Borbényi Z, et al. Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol Immunol Hung. 2005;52(3-4):463–475. doi:https://doi.org/10.1556/AMicr.52.2005.3-4.15.
- Kádár K, Demeter J, Andrikovics H, et al. TNF-alpha promoter gene polymorphism in patients with myelodysplastic syndrome. Acta Haematol. 2005;113(4):262–264. doi:https://doi.org/10.1159/000084681.
- The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses [EB/OL]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- Moldoveanu E, Moicean A, Vidulescu C, et al. Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines. J Cell Mol Med. 2003;7(3):313–321. doi:https://doi.org/10.1111/j.1582-4934.2003.tb00232.x.
- Kiss C, Benko I, Kovács P. Leukemic cells and the cytokine patchwork. Pediatr Blood Cancer. 2004;42(2):113–121. doi:https://doi.org/10.1002/pbc.10436.
- Stifter G, Heiss S, Gastl G, et al. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol. 2005;75(6):485–491. doi:https://doi.org/10.1111/j.1600-0609.2005.00551.x.
- Serio B, Selleri C, Maciejewski JP. Impact of immunogenetic polymorphisms in bone marrow failure syndromes. Mini Rev Med Chem. 2011;11(6):544–552. doi:https://doi.org/10.2174/138955711795843356.
- Camara-Lemarroy CR, Salas-Alanis JC. The role of tumor necrosis factor-α in the pathogenesis of vitiligo. Am J Clin Dermatol. 2013;14(5):343–350. doi:https://doi.org/10.1007/s40257-013-0039-3.
- Ma HJ, Fu SC, Xiao A, et al. The associations of CYP19A1 rs700518 polymorphism with bone mineral density and risk of osteoporosis: a meta-analysis. Gynecol Endocrinol. 2020;36(7):626–631. doi:https://doi.org/10.1080/09513590.2020.1727431.
- Huebner C, Browning BL, Petermann I, et al. Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflamm Bowel Dis. 2009;15(12):1784–1793. doi:https://doi.org/10.1002/ibd.21019.
- Kim JH, Jeon YJ, Rah H, et al. Tumor necrosis factor-alpha promoter polymorphisms are associated with idiopathic primary ovarian insufficiency in Korean women. Fertil Steril. 2012;98(5):1260–1265. e52. doi:https://doi.org/10.1016/j.fertnstert.2012.07.1111.
- Kampman O, Anttila S, Illi A, et al. Interaction of tumor necrosis alpha - G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2005;255(4):279–283. doi:https://doi.org/10.1007/s00406-004-0560-8.
- Li Y, Lin Y. Tumor necrosis factor alpha-308G/A polymorphism and the risk of multiple myeloma: a meta-analysis of pooled data from twelve case-control studies. Turk J Haematol. 2019;36(2):72–80. doi:https://doi.org/10.4274/tjh.galenos.2019.2018.0238.
- Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol. 1999;66(4):562–566. doi:https://doi.org/10.1002/jlb.66.4.562.
- Wang X, Zhang H, Cao X, et al. Gene-disease association study of tumor necrosis factor-α G-308A gene polymorphism with risk of major depressive disorder: a systematic review and meta-analysis. Brain Behav. 2020;10(6):e01628. doi:https://doi.org/10.1002/brb3.1628.
- Kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol. 2000;114(6):1180–1183. doi:https://doi.org/10.1046/j.1523-1747.2000.00001.x.
- Tian X, Ma P, Sui C, et al. Comprehensive assessment of the association between tumor necrosis factor alpha G238A polymorphism and liver cancer risk. Tumour Biol. 2014;35(1):103–109. doi:https://doi.org/10.1007/s13277-013-1012-8.